CNTO1959CRD3004: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants With Moderately to Severely Active Crohn's Disease
CNTO1959CRD3004: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.
Inclusion Criteria:
Exclusion Criteria:
North Massapequa, New York 11758, United States
Campinas, 13060-904, Brazil
Porto Alegre, 90160-092, Brazil
São José do Rio Preto, 15090-000, Brazil
Hangzhou, 310006, China
Hilleroed, 3400, Denmark
Budapest, 1125, Hungary
Pécs, 7624, Hungary
Fukui-ken, 910-8526, Japan
Gunma, 371-0034, Japan
Higashi-Ibaraki, 311-3193, Japan
Iizuka-shi, 820-8505, Japan
Nakagami-gun, 901-2132, Japan
Sunto-gun, 411-8611, Japan
Irbid, 22110, Jordan
Johor Bharu, 80100, Malaysia
Torun, 87 100, Poland
Włocławek, 87-800, Poland
Dongdaemun-gu, 02447, South Korea
Kaoshiung, 80756, Taiwan